The approval of ¹⁷⁷Lu-PSMA-617 for adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitors and ...

Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.

Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when treated with a ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...

Members of Duran Duran offered an update on founding member and legendary guitarist Andy Taylor’s battle with stage-four ...

MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d ...

Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly improves overall survival in patients with metastatic ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

The 63-year-old musician revealed his stage 4 prostate cancer diagnosis in November 2022, saying his cancer was “asymptomatic ...